Lupin and Zydus partner to combat liver disease and hepatitis

Lupin and Zydus Lifesciences announced they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces...